Skip to main content
. 2019 Apr 11;11(4):519. doi: 10.3390/cancers11040519

Figure 1.

Figure 1

Gemcitabine (GEM) effects on survival: Treatment was performed at 72 h using different GEM doses. MT-CHC01: parental cells; MT-CHC01R1.5: GEM resistant cells; MT-CHC01R1.5 no Gem: MT-CHC01R1.5 resistant clone deprived from GEM for 10 days and re-exposed to escalating doses of the drug for 72 h. All the experiments were conducted in three independent experiments in quadruplicate. Error bars represent mean and SD. **** p = 0.00001.